International Clinical Trial: A single-center, double-cohort, open-label clinical trial evaluating the safety and efficacy of vebecotota monoclonal antibody for injection, either in combination or alone with putrilimab injection, in patients with recurrent or metastatic salivary gland cancer

Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118473) titled 'A single-center, double-cohort, open-label clinical trial evaluating the safety and efficacy of vebecotota monoclonal antibody for injection, either in combination or alone with putrilimab injection, in patients with recurrent or metastatic salivary gland cancer' on Feb. 6.

Study Type: Interventional study

Study Design: Non randomized control

Primary Sponsor: Fudan University Shanghai Cancer Center

Condition: Salivary Gland Cancer

Intervention: The single-drug ACC group:Intravenous injection of MRG003 The non-ACC single-drug group:Intravenous injection of MRG003 Combined ACC group:Injection of MRG003 + Put...